The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
 
Michael C. Heinrich
Stock and Other Ownership Interests - MolecularMD
Honoraria - Novartis
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; MolecularMD; Novartis; Pfizer
Research Funding - Blueprint Medicines (Inst); Deciphera (Inst)
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
Expert Testimony - Novartis
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Margaret von Mehren
Consulting or Advisory Role - Blueprint Medicines; CytRx Corporation; deciphera; Janssen Oncology
Research Funding - ArQule
Travel, Accommodations, Expenses - Arog
Other Relationship - NCCN
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Lilly; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Yoon-Koo Kang
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; LSK Biopharma; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Patrick Schoffski
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Ferry Eskens
Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Roche
Travel, Accommodations, Expenses - Pfizer
 
Olivier Mir
Stock and Other Ownership Interests - Transgene
Honoraria - Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche; SERVIER; Vifor Pharma
Speakers' Bureau - Lilly; Roche
Travel, Accommodations, Expenses - Pfizer; PharmaMar; Roche
 
Philippe Alexandre Cassier
Honoraria - Amgen; Blueprint Medicines; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Roche
 
Cesar Serrano
Honoraria - Bayer
Consulting or Advisory Role - Blueprint Medicines; Deciphera
Research Funding - Bayer; Deciphera; Pfizer
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625
 
Jonathan C. Trent
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Janssen; Lilly; Novartis
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Shreyaskumar Patel
Consulting or Advisory Role - CytRx Corporation; EMD Serono; Epizyme; Immune Design; Janssen; Lilly; Michael J. Hennessy Company; Novartis; PharmaMar
Research Funding - Bavarian Nordic; Blueprint Medicines; Eisai; Janssen
Patents, Royalties, Other Intellectual Property - UpToDate
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Eyal Meiri
No Relationships to Disclose
 
Teresa Zhou
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Khalid Kevin Mamlouk
Employment - Merrimack
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Clovis Oncology; Jounce Therapeutics; Merrimack
Consulting or Advisory Role - Blue Earth Diagnostics; Blueprint Medicines; Ipsen
 
Maria Roche
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I); Allergan (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; deciphera; Lilly
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice